EGFR Inhibitors for the Treatment of Head and Neck Cancer
Patent Information
- Application Number
- JP2023575997
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-06-10
- Filing Date
- 2022-06-09
- Publication Date
- 2024-11-07
- Estimated Expiration
- 2042-06-09
Smart Images

Figure 0007579465000006 
Figure 0007579465000007 
Figure 0007579465000001
Abstract
Description
[Technical field]
[0001] The present invention relates to the treatment of head and neck cancer. [Background technology]
[0002] 2. Background of the Invention Great strides have been made in the treatment of solid tumors in recent years. However, many forms of cancer remain incurable and resistant to standard treatments. Head and neck cancer is a highly incurable cancer with limited treatment options. A particularly incurable cancer is recurrent head and neck squamous cell carcinoma. This cancer has a high mortality rate, significant morbidity (especially impaired ability to speak and swallow), and no successful treatments are available.
[0003] Head and neck cancer and recurrent and / or metastatic head and neck squamous cell carcinoma (especially when the recurrent and / or metastatic head and neck squamous cell carcinoma is recurrent head and neck squamous cell carcinoma) are difficult to treat for many reasons. The cancer is invasive and multifocal, which can prevent effective resection. Head and neck cancer and recurrent and / or metastatic head and neck squamous cell carcinoma (especially when the recurrent and / or metastatic head and neck squamous cell carcinoma is recurrent head and neck squamous cell carcinoma) can also be resistant to standard therapies.
[0004] (3-Ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. The structure of NRC-2694 is shown below.
[0005] [ka]
[0006] NRC-2694 has been found to be effective against certain cancer types (WO2009 / 090661A1 and WO2011 / 021212A1). NRC-2694 has also been found to cause low to moderate inhibition of the growth of head and neck cancer cell lines implanted in athymic female mice (Parkinson et al, Antiviral Research 74(2007) 43-50).
[0007] NRC-2694 can be administered as NRC-2694 dihydrochloride (known as NRC-2694-A).
[0008] The effectiveness of a particular therapeutic agent against different cancers is unpredictable. Kinase inhibitors that are active against one cancer have been found to be inactive against other cancer types. There remains a need to identify active agents that are effective in the treatment of head and neck cancer, particularly agents that can cause tumor regression, reducing tumor size. A reduction in tumor size is particularly important in head and neck cancer, as it is more likely that the patient will be able to speak and swallow more easily. There also remains a need to identify active agents that are effective in the treatment of recurrent head and neck squamous cell carcinoma. Summary of the Invention
[0009] NRC-2694 has been found to be an effective treatment for head and neck cancer and head and neck squamous cell carcinoma. NRC-2694 can reduce the size of tumors associated with head and neck cancer and improve patient outcomes. This is an important advance in the treatment of head and neck cancer. NRC-2694 can also inhibit the growth of tumors and / or reduce the size of tumors associated with head and neck squamous cell carcinoma and improve patient outcomes. This is an important advance in the treatment of head and neck squamous cell carcinoma, a cancer with a high mortality rate and few effective treatment options.
[0010] Thus, the present invention provides a compound for use in treating recurrent and / or metastatic head and neck squamous cell carcinoma (R / M HNSCC) in a patient, wherein the compound is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutically acceptable salt thereof. Preferably, the recurrent and / or metastatic head and neck squamous cell carcinoma is recurrent head and neck squamous cell carcinoma.
[0011] The present invention therefore further provides a compound for use in treating head and neck cancer in a patient, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutically acceptable salt thereof; and a method of treating head and neck cancer comprising reducing the size of one or more tumors associated with head and neck cancer. [Brief description of the drawings]
[0012] [Figure 1] Figure 1 shows Kaplan-Meier estimates of progression-free survival. [Diagram 2] FIG. 2 shows efficacy results for patients who continued to stage-II (monotherapy).
[0013] Brief explanation of the table Table 1 provides a summary of the tumor evaluations for the five patients with recurrent head and neck squamous cell carcinoma discussed in Example 1. Table 2 provides the demographics of the patients in the study of Example 2. Table 3 provides progression-free survival (PFS) data for the study of Example 2. Table 4 provides the objective response rate (ORR) data for the study of Example 2.
[0014] Detailed Description of the Invention NRC-2694 has the systematic name (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine. NRC-2694 may also be referred to as N-(3-ethynylphenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine. NRC-2694 and its salts may be prepared by standard synthetic techniques. The synthesis of NRC-2694 is described in WO2011 / 021212A1.
[0015] The compound is NRC-2694 or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salt is typically a pharmaceutically acceptable acid addition salt. Typically, the compound is a hydrochloride salt of NRC-2694. For example, the compound may be a monohydrochloride salt of NRC-2694 (NRC-2694-B) or a dihydrochloride salt of NRC-2694 (NRC-2694-A). Preferably, the compound is a dihydrochloride salt of NRC-2694 (NRC-2694-A).
[0016] The cancer to be treated is head and neck cancer. The head and neck cancer may be head and neck carcinoma, head and neck lymphoma, head and neck adenocarcinoma, or head and neck sarcoma. Typically, the cancer is head and neck carcinoma.
[0017] The cancer to be treated may be, for example, head and neck squamous cell carcinoma. Other forms of head and neck cancer include head and neck lymphoma, head and neck adenocarcinoma, and head and neck sarcoma.
[0018] The cancer to be treated may be a recurrent and / or metastatic cancer, in particular a recurrent and / or metastatic head and neck squamous cell carcinoma. Thus, the head and neck squamous cell carcinoma may be a head and neck squamous cell carcinoma that has recurred and / or metastasized after treatment of a previous stage of head and neck squamous cell carcinoma in the patient. Preferably, the cancer to be treated is a recurrent cancer, in particular a recurrent head and neck squamous cell carcinoma. Thus, the head and neck squamous cell carcinoma may be a head and neck squamous cell carcinoma that has recurred after treatment of a previous stage of head and neck squamous cell carcinoma in the patient. Typically, the recurrent tumor or lesion develops within 10 years after the end of treatment that removes, destroys or reduces the size of the initial tumor or lesion. For example, the patient may already have head and neck squamous cell carcinoma within a period of 10 years, 5 years, or 2 years before starting treatment of the recurrent head and neck squamous cell carcinoma with the compound.
[0019] Recurrent head and neck squamous cell carcinoma may be head and neck squamous cell carcinoma that recurs after previous treatment for head and neck squamous cell carcinoma.For example, the patient may have previously been treated for head and neck squamous cell carcinoma with EGFR inhibitor (e.g. erlotinib, gefitinib, lapatinib, cetuximab or vandetanib, preferably cetuximab), immunotherapy (e.g. pembrolizumab or nivolumab), tumor diagnostic therapy (e.g. larotrectinib), or chemotherapy (e.g. 5-fluorouracil, gemcitabine, cisplatin, carboplatin, paclitaxel or docetaxel).
[0020] For example, the patient may have been previously treated with cetuximab, pembrolizumab, or nivolumab for head and neck cancer (e.g., head and neck squamous cell carcinoma). The patient may have been previously treated with radiation therapy or surgery for head and neck cancer or head and neck squamous cell carcinoma. The patient may have been previously treated with chemotherapy, for example, with a combination of paclitaxel and cisplatin or carboplatin.
[0021] Patients with head and neck cancer (e.g., recurrent head and neck squamous cell carcinoma) typically have one or more tumors (lesions or carcinomas) in the head and neck. The patient may have one or more tumors selected from laryngeal tumors, hypopharyngeal tumors, nasal tumors, paranasal tumors, nasopharyngeal tumors, oral tumors, oropharynx tumors, and salivary gland tumors. The patient may have laryngeal cancer, hypopharyngeal cancer, nasal tumors, paranasal tumors, nasopharyngeal tumors, oral tumors, oropharynx tumors, or salivary gland tumors.
[0022] The head and neck cancer may be a metastatic cancer. For example, the head and neck cancer may be a metastatic recurrent head and neck squamous cell carcinoma. The head and neck cancer may have metastasized to lymph nodes, lungs, brain, liver or bone, or other organs of the human body.
[0023] The head and neck cancer may be at any stage. The head and neck cancer may be at stage I, stage II, stage III or stage IV cancer. For example, the head and neck cancer may be at stage III or stage IV cancer.
[0024] The recurrent head and neck squamous cell carcinoma may be metastatic recurrent head and neck squamous cell carcinoma. The recurrent head and neck squamous cell carcinoma may have metastasized to lymph nodes, lungs, brain, liver or bones, or other organs of the human body.
[0025] The recurrent head and neck squamous cell carcinoma may be at any stage. The recurrent head and neck squamous cell carcinoma may be at stage I, stage II, stage III or stage IV cancer. For example, the recurrent head and neck squamous cell carcinoma may be at stage III or stage IV cancer.
[0026] Treating head and neck cancer may include reducing the size of one or more tumors associated with head and neck cancer. Thus, the treatment may cause tumor regression of head and neck cancer. Treating head and neck cancer may include reducing the number of tumors or lesions present in the head and neck of the patient. Treating head and neck cancer may include alleviating, improving, or preventing the worsening of symptoms of head and neck cancer. Treating head and neck cancer may further include inhibiting the progression of head and neck cancer. Treating head and neck cancer may further include preventing metastasis of head and neck cancer. Treating head and neck cancer may include reducing the size of tumors associated with metastasis of head and neck cancer.
[0027] The treatment of recurrent and / or metastatic head and neck squamous cell carcinoma may include alleviating, improving or preventing the worsening of symptoms of recurrent and / or metastatic head and neck squamous cell carcinoma. The treatment of recurrent head and neck squamous cell carcinoma may include alleviating, improving or preventing the worsening of symptoms of recurrent head and neck squamous cell carcinoma. Typically, treating recurrent head and neck squamous cell carcinoma includes inhibiting the progression of recurrent head and neck squamous cell carcinoma. Treating recurrent head and neck squamous cell carcinoma may include preventing or inhibiting the growth of tumors associated with recurrent head and neck squamous cell carcinoma or reducing the size of tumors associated with recurrent head and neck squamous cell carcinoma. Treating recurrent head and neck squamous cell carcinoma may include preventing metastasis of recurrent head and neck squamous cell carcinoma. Preferably, treating recurrent head and neck squamous cell carcinoma includes reducing the size of tumors associated with recurrent head and neck squamous cell carcinoma. Thus, treatment may cause regression of recurrent head and neck squamous cell carcinoma tumors. Treating recurrent head and neck squamous cell carcinoma may include reducing the number of tumors or lesions present in the head and neck of a patient. Treating recurrent head and neck squamous cell carcinoma may include reducing the size of tumors associated with metastases of recurrent head and neck squamous cell carcinoma.
[0028] When the treatment reduces the size of the tumor associated with head and neck cancer or recurrent and / or metastatic squamous cell carcinoma of the head and neck (preferably, the recurrent and / or metastatic squamous cell carcinoma of the head and neck is recurrent squamous cell carcinoma of the head and neck), the size of the tumor is typically reduced by at least 10% from baseline. The baseline is the size of the tumor on or before the day treatment with the compound is first started. For example, the baseline can be the size of the tumor measured by CT, MRI or PET scan before treatment is first started (e.g., within 2 weeks before treatment is first started). The size of the tumor is typically measured according to RECIST criteria version 1.1 (e.g., as described in Eisenhauer et al, European Journal of Cancer 45(2009) 228-247). Thus, the size of the tumor can be reduced by at least 10 mm.
[0029] The response to treatment with the compound may be a complete response, a partial response, or stable disease according to RECIST version 1.1. Preferably, the response is a partial response or a complete response. A complete response may include the disappearance of all target lesions. A partial response may include a reduction in the sum of the diameters of the target lesions by at least 30%.
[0030] The treatment may achieve progression free survival of at least 45 days, at least 60 days, at least 120 days, or at least 180 days.
[0031] The reduction in tumor size may be greater than or equal to 20%, greater than or equal to 30%, or greater than or equal to 50% relative to baseline. The reduction in tumor size may be observed after 30 days of treatment, after 45 days of treatment, or after 60 days of treatment.
[0032] The compound can be effective for treating head and neck cancer in patients who have not been successfully treated with other methods.Therefore, the head and neck cancer can be head and neck cancer that is resistant to radiation therapy and / or chemotherapy.For example, the patient can have previously undergone radiation therapy or chemotherapy for the treatment of head and neck cancer, and have failed to respond to radiation therapy or chemotherapy or have stable disease.
[0033] The compound is found to be effective in treating recurrent head and neck squamous cell carcinoma in patients who have failed other therapies.Therefore, recurrent head and neck squamous cell carcinoma may be recurrent head and neck squamous cell carcinoma that is resistant to radiotherapy and / or chemotherapy.For example, the patient may have previously undergone radiotherapy or chemotherapy to treat recurrent head and neck squamous cell carcinoma, and may have no response or stable disease to radiotherapy or chemotherapy.
[0034] The head and neck cancer may be resistant to treatment with erlotinib and / or gefitinib. The recurrent head and neck squamous cell carcinoma may be resistant to treatment with erlotinib and / or gefitinib.
[0035] The treatment may, for example, reduce multidrug resistance during chemotherapy. For example, the treatment may reduce resistance to cisplatin, carboplatin, or paclitaxel.
[0036] The patient may have at least one line of cancer therapy before the treatment with the compound. The patient may have at least two lines of cancer therapy before the treatment with the compound. The line of cancer therapy may be selected from the following: treatment with EGFR inhibitors other than NRC-2694 (e.g., erlotinib, gefitinib, lapatinib, cetuximab or vandetanib, preferably cetuximab), treatment with immunotherapy (e.g., pembrolizumab or nivolumab), treatment with tumor diagnostic therapy (e.g., larotrectinib), treatment with chemotherapy (e.g., gemcitabine, 5-fluorouracil, cisplatin, carboplatin, paclitaxel or docetaxel).
[0037] The patient may have been diagnosed with head and neck cancer for 6 months or more, 1 year or more, 2 years or more, or 3 years or more. The patient may have been diagnosed with recurrent and / or metastatic head and neck squamous cell carcinoma for 1 month or more, 6 months or more, 1 year or more, 2 years or more, or 3 years or more. In particular, the patient may have been diagnosed with recurrent head and neck squamous cell carcinoma for 1 month or more, 6 months or more, 1 year or more, 2 years or more, or 3 years or more.
[0038] The patient is typically a human patient. The patient may be male or female. The patient is typically at least 18 years old, for example 30 to 70 years old or 40 to 60 years old.
[0039] Compounds may be administered in various dosage forms.For example, compounds may be administered orally as tablets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.Alternatively, compounds may be administered parenterally, for example, subcutaneously, intravenously, intramuscularly, intrasternally, transdermally, or by drip infusion.Compounds may also be administered as suppositories.
[0040] The compounds are typically administered orally. The compounds are preferably administered in tablet form.
[0041] Compounds are typically formulated for administration with pharmaceutically acceptable carriers or diluents.For example, solid oral forms may contain active compounds together with diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants such as silica, talc, stearic acid, magnesium or calcium stearate, and / or polyethylene glycol; binders such as starch, gum arabic, gelatin, methylcellulose, carboxymethylcellulose or polyvinylpyrrolidone; disintegrants such as starch, alginic acid, alginates or sodium starch glycolate; effervescent agents; dyes; sweeteners; wetting agents such as lecithin, polysorbates, lauryl sulfates; and non-toxic and pharmacologically inactive substances that are generally used in pharmaceutical formulations.Such pharmaceutical preparations may be prepared by known methods, such as mixing, granulation, tableting, sugar-coating or film-coating processes.
[0042] Liquid dispersions for oral administration may be syrups, emulsions or suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and / or mannitol and / or sorbitol.
[0043] Suspensions and emulsions may contain, as a carrier, for example, natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharma- ceutically acceptable carrier, for example, sterile water, olive oil, ethyl oleate, glycols, for example, propylene glycol, and, if desired, an appropriate amount of lidocaine hydrochloride.
[0044] Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably may be in the form of sterile, aqueous, isotonic saline solutions.
[0045] The compound may be administered to the patient as many times as necessary to treat head and neck cancer or recurrent and / or metastatic head and neck squamous cell carcinoma (wherein preferably, the recurrent and / or metastatic head and neck squamous cell carcinoma is recurrent head and neck squamous cell carcinoma). The compound may be administered once or twice a week, or once, twice, three or four times a day. Typically, the compound is administered to the patient once or twice a day. Preferably, the compound is administered to the patient once a day.
[0046] A therapeutically effective amount of the compound is administered to the patient. Typical dosages are 1 mg / day to 1000 mg / day, depending on the age and weight of the patient to be treated, the severity of recurrent head and neck squamous cell carcinoma, frequency of administration and route of administration. Typically, the compound is administered to human patients at a dosage of 50 mg / day to 500 mg / day. Preferably, the compound is administered to patients at a dosage of 100 mg / day to 400 mg / day. For example, the daily dosage can be 75 mg / day to 125 mg / day, 125 mg / day to 175 mg / day, 175 mg / day to 225 mg / day, 225 mg / day to 275 mg / day, 275 mg / day to 325 mg / day, 325 mg / day to 375 mg / day, 375 mg / day to 425 mg / day, or 425 mg / day to 475 mg / day. The daily dose may be about 100 mg / day, about 125 mg / day, about 150 mg / day, about 175 mg / day, about 200 mg / day, about 225 mg / day, about 250 mg / day, about 275 mg / day, about 300 mg / day, about 325 mg / day, about 350 mg / day, about 375 mg / day, about 400 mg / day, about 425 mg / day, about 450 mg / day, about 475 mg / day, or about 500 mg / day. The compound may be administered to a human patient under fasting or fed conditions. The compound may be administered to a human patient with or without food.
[0047] The compound may be administered to the patient at a dose of 200 mg / day to 400 mg / day. The compound may be administered to the patient at a dose of 250 mg / day to 350 mg / day. Preferably, the compound may be administered to the patient at a dose of 275 mg / day to 325 mg / day. For example, about 300 mg of the compound may be administered per day. The compound may be administered in one or more doses per day. Typically, the compound is administered to the patient in an amount of 275 mg to 325 mg as a single dose once per day. The compound may be administered once per day for at least 5 days, for example, for 1 month to 6 months.
[0048] The compound may be administered as a monotherapy. Alternatively, the compound may be administered as a part of a combination therapy, for example, with radiation therapy, immunotherapy (e.g., pembrolizumab or nivolumab), tumor diagnostic therapy (e.g., larotrectinib), chemotherapy (e.g., 5-fluorouracil, gemcitabine, cisplatin, carboplatin, paclitaxel or docetaxel) or a combination thereof. The compound may be administered as a part of a combination therapy with chemotherapy, for example, with one or more of 5-fluorouracil, gemcitabine, cisplatin, carboplatin, paclitaxel and docetaxel. The chemotherapy may include administration of one or more of cisplatin, carboplatin and paclitaxel. The compound may be administered in combination with, for example, (a) cisplatin and paclitaxel, or (b) carboplatin and paclitaxel.
[0049] The combination therapy may include administering the two treatments simultaneously or separately. For example, the patient may be undergoing chemotherapy at the time of administering the compound. The chemotherapy may be administered, for example, separately from the treatment with the compound, for example, once every 2 to 5 weeks.
[0050] Thus, the present invention provides a compound for use in the treatment defined herein in combination with chemotherapy. The compound may be for use in the treatment defined herein in combination with (a) cisplatin and paclitaxel or (b) carboplatin and paclitaxel. The present invention also provides a chemotherapy for use in the treatment defined herein in combination with the compound. Also provided is a product comprising (i) the compound and (ii) cisplatin and paclitaxel or carboplatin and paclitaxel for use in the simultaneous, sequential or separate treatment of a disease defined herein. When the compound is administered, the patient may be undergoing chemotherapy with (a) cisplatin and paclitaxel or (b) carboplatin and paclitaxel.
[0051] Cisplatin or carboplatin is administered at a dose of 25 mg / m2 of total body surface area. 2 to 175 mg / m 2 , e.g., 75 mg / m2 of total body surface area 2 to 125 mg / m 2 Paclitaxel may be administered at a dose of 100 mg / m2 of total body surface area. 2 to 250 mg / m 2 , e.g., 150 mg / m2 of total body surface area 2 to 200 mg / m 2 may be administered at a dose of
[0052] The present invention also provides a method of treating head and neck cancer in a patient, comprising administering to the patient a compound, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutically acceptable salt thereof, and treating head and neck cancer comprises reducing the size of one or more tumors associated with head and neck cancer. The present invention also provides a use of a compound in the manufacture of a medicament for treating head and neck cancer in a patient, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutically acceptable salt thereof, and treating head and neck cancer comprises reducing the size of one or more tumors associated with head and neck cancer. The cancer, patient, compound and treatment may be as defined herein for the compound for use according to the present invention.
[0053] The present invention also provides a method for treating recurrent and / or metastatic head and neck squamous cell carcinoma in a patient, comprising administering to the patient a compound, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. In particular, the present invention also provides a method for treating recurrent head and neck squamous cell carcinoma in a patient, comprising administering to the patient a compound, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The present invention also provides the use of a compound in the manufacture of a medicament for the treatment of recurrent and / or metastatic head and neck squamous cell carcinoma in a patient, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. In particular, the present invention also provides the use of a compound in the manufacture of a medicament for the treatment of recurrent head and neck squamous cell carcinoma in a patient, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharmaceutically acceptable salt thereof. The carcinoma, the patient, the compound and the treatment may be as defined herein for the compound for use according to the present invention.
[0054] The present invention is further illustrated by the following examples, which are not intended to limit the scope of the claims. EXAMPLES
[0055] Example 1 summary We conducted a phase I clinical trial to evaluate the safety, pharmacokinetics, and antitumor activity of NRC-2694-A (NRC-2694 dihydrochloride) in patients with recurrent head and neck squamous cell carcinoma.
[0056] the purpose Primary: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of NRC-2694-A administered orally once daily. Secondary: Evaluate single and multiple dose pharmacokinetics and antitumor activity of NRC-2694-A.
[0057] Study population Patients with a confirmed diagnosis of advanced solid malignancies for which no standard options exist.
[0058] Eligibility Criteria The inclusion criteria are as follows: - Patient is 18 years of age or older with an expected life expectancy of 8 weeks or more. - Had an ECOG performance score of ≤2. - Adequate bone marrow reserve (at least 3,000 WBC / mm 3 , neutrophil count 2000 / mm 3 or more, platelet count 1,00,000mm 3 and hemoglobin level 8.0 g / dL or higher), renal function (serum creatinine normal), liver function [total bilirubin level 2x upper limit of normal (UNL) or lower and serum transaminase level 2.5x UNL or lower / 5x UNL in case of liver metastasis and / or obstructive jaundice. Subjects must have negative HIV, HbsAg and pregnancy (if female) tests. - Patients have not received chemotherapy within 14 days (6 weeks for nitrosoureas or mitomycin C), radiation therapy within 3 weeks, or surgery within 2 weeks prior to treatment. - Patients willing to practice contraception during and for 2 months after treatment.
[0059] The exclusion criteria were as follows: -Patients with major illness not adequately controlled by current treatment, such as active cardiac, hepatic, endocrine, renal or psychiatric disease. - Patients with brain metastases or primary CNS malignancies. -Combination cancer treatments (radiotherapy, chemotherapy, etc.). - Pregnant or lactating patients - The presence of any condition, such as abnormal laboratory test values, that may place the subject at unacceptable risk if included in the study and may obscure the assessment of toxicity or changes in drug metabolism - Any disorder of gastrointestinal function that may significantly alter the absorption of the study drug, and the use of medications that alter gastric pH; (mild antacids taken 4 hours before or after study drug administration are permitted)
[0060] Study design An open-label, prospective, non-randomized, multicenter, dose-escalation trial was conducted. The starting dose selected in this study was 100 mg / day, with a maximum dose of 500 mg / day. Eligible subjects were admitted to a single hospital unit for 12 days, after which those who tolerated the drug were treated on an outpatient (ambulatory) basis.
[0061] Prognostic evaluation Safety: Evaluations were performed within 7 days before study drug administration and then on days 12, 18, 24, 30, 45, 60, 75, and 90. However, for evaluation of DLT and MTD, safety data from the first 30 days were considered.
[0062] Pharmacokinetic evaluation: Evaluation of NRC-2694 in plasma was performed using a validated LC-MS / MS method. Based on the plasma concentration data, non-compartmental pharmacokinetic variables, namely area under the curve (AUC), plasma peak concentration (C max ), time to peak plasma concentration (T max ), and elimination rate constants, distribution volumes, half-lives and clearance were calculated for single doses (day 1) and at steady state (day 12). Blood samples were collected in vacutainers containing K2EDTA before dosing and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 hours.
[0063] Tumor assessment: Change from baseline in the size of evaluable tumors was assessed according to RECIST criteria (version 1.1).
[0064] result A summary of the tumor evaluations of the five patients with recurrent head and neck squamous cell carcinoma is shown in Table 1 .
[0065] [Table 1]
[0066] Four patients with recurrent head and neck squamous cell carcinoma completed the 120-day trial. One patient had a partial response with a reduction in tumor size by RECIST criteria (tumor regression). The remaining patients had stable disease.
[0067] Pharmacokinetic data showed a dose-dependent increase in concentrations from 100 mg / day to 500 mg / day for both Day-1 and Day-12 concentrations.
[0068] conclusion Once-daily administration of NRC-2694-A demonstrated a fairly favorable safety profile. Dose proportionality was observed for the pharmacokinetics of NRC-2694-A. The MTD of NRC-2694-A was 400 mg / day. NRC-2694-A demonstrated favorable objective responses in patients with recurrent head and neck squamous cell carcinoma, causing tumor size reduction or stasis in tumor size.
[0069] Example 2 A phase II clinical trial was conducted to evaluate the efficacy and safety of NRC-2694-A in patients with recurrent head and neck squamous cell carcinoma.
[0070] Background information Head and neck cancer begins in the squamous cells that line the moist mucosal surfaces inside the head and neck region (e.g., inside the mouth, nose, and throat). There are an estimated 66,470 new cases of oral, pharyngeal, or laryngeal cancer annually, accounting for approximately 3.5% of new cancer cases in the United States. An estimated 15,050 deaths from head and neck (H&N) cancer may occur during the same period. Squamous cell carcinoma or its variants are the histopathological type in more than 90% of these tumors.
[0071] NRC-2694-A is an organic small molecule with the IUPAC name N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine dihydrochloride. It is an orally administered tyrosine kinase inhibitor that belongs to the quinazoline class of EGFR inhibitors. Amplified EGFR signaling is frequently found in human tumors and is caused by a variety of mechanisms. Because amplified EGFR signaling plays a key role in carcinogenesis, inhibiting this process is a rational approach in developing new chemical entities for the treatment of such malignancies.
[0072] Research purpose PRIMARY OBJECTIVE:The primary objective is to evaluate the efficacy of NRC-2694-A plus platinum and paclitaxel combination regimen compared with platinum and paclitaxel regimen alone in terms of progression-free survival (PFS) in patients with recurrent and / or metastatic head and neck squamous cell carcinoma (R / M HNSCC). Secondary Objectives: The secondary objectives were (a) to compare the objective response rate in patients with R / M HNSCC treated with NRC-2694-A plus platinum plus paclitaxel regimen versus platinum plus paclitaxel regimen alone, and (b) to compare the safety and tolerability of the two regimens.
[0073] Test Method This study was an open-label, prospective, randomized, active-controlled, multicenter, phase II trial of NRC-2694-A in patients with histologically / cytologically confirmed HNSCC with radiological progression (recurrence and / or metastasis).
[0074] Patients aged 18 to 65 years with recurrent and / or metastatic disease and a life expectancy of 3 months or more who were planned to receive a cisplatin / carboplatin and paclitaxel regimen were eligible for the study. Patients who met all inclusion and exclusion criteria were randomly assigned to receive either chemotherapy plus NRC-2694-A (study drug arm) or chemotherapy alone (control arm). -Arm-I: NRC-2694-A + cisplatin / carboplatin and paclitaxel. -Arm-II (control group): Cisplatin / carboplatin and paclitaxel
[0075] During the study, NRC-2694-A, 300 mg, was administered once daily in the morning with 240 mL of water, with or without food. The cisplatin dose was 100 mg / m2 of body surface area. 2 Alternatively, carboplatin was administered at a dose of 1 hour based on a target area under the curve (AUC) equivalent to 5 mg / mL / min. The choice of platinum compound was at the investigator's discretion and was dependent on the type of platinum administered in prior therapy, with repeated dosing avoided. Paclitaxel was administered at a dose of 175 mg / m2 of body surface area. 2 The dose was given intravenously over 3 hours. -Monotherapy: After completing six cycles of chemotherapy in either the control or experimental arm, patients received NRC-2694-A, 300 mg, once daily as monotherapy.
[0076] Eligibility Criteria Inclusion criteria 1. Patients aged 18 to 65 years with recurrent and / or metastatic disease with a life expectancy of 3 months or more, planned to receive a cisplatin / carboplatin and paclitaxel regimen, even in the palliative setting. 2.ECOG (Eastern Co-operative Oncology Group) performance status of 2 or less. 3. Histologically confirmed squamous cell carcinoma of the head and neck. Primary sites include the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, and paranasal sinuses. 4. Adequate bone marrow reserve (WBC (white blood cell) at least 3,000 / mm 3 , neutrophil count 2000 / mm 3 Above, platelet count 1,00,000 / mm 3or higher and hemoglobin level 8.0 g / dL), renal function (serum creatinine normal), liver function [total bilirubin level less than 2 times the upper limit of normal (UNL) and serum transaminase level less than 2.5 times the UNL / less than 5 times in case of liver metastasis and / or obstructive jaundice]. 5. Patients who have not received chemotherapy within 30 days (6 weeks for nitrosoureas or mitomycin C), radiation therapy within 3 weeks, or surgery within 2 weeks prior to administration. 6.Measurable disease according to revised RECIST criteria (version 1.1). 7. Patients who received primary radiation therapy were eligible if their local recurrence was within the radiation field and at least 6 months after completing treatment. If the recurrence was outside the radiation field, patients were eligible if at least 3 months after completing treatment. 8. Willing to practice contraception during and for 2 months after treatment. 9. Patients with negative HIV, HBsAg, HCV and pregnancy (if female) tests.
[0077] Exclusion criteria: 1. Patients with major illness that is not adequately controlled with current treatment, such as active cardiac, hepatic, endocrine, renal or psychiatric disease. 2. Patients with brain metastases or primary CNS (central nervous system) malignancies. Radiological evaluation of brain metastases was performed only if the patient was symptomatic. 3. Prior EGFR targeted therapy, prior investigational agent for recurrent or metastatic disease, other concomitant investigational agent, other concomitant anticancer therapy.
[0078] Evaluation criteria Efficacy assessment: -Tumor response was assessed by CT or MRI at baseline and at the end of every 6 weeks after initiation of treatment (before the start of the next cycle) until disease progression. - Progression-free survival was defined as the time from the date of randomization to the date of progression or death, whichever occurred first. -Disease progression was assessed according to RECIST version 1.1 criteria.2 – Objective response rate was the percentage of patients in each arm who achieved a complete or partial response to treatment. - Complete response (CR): Disappearance of all target lesions. -Partial Response (PR): At least a 30% reduction in the sum of the diameters of target lesions.
[0079] Safety rating: Adverse events were monitored throughout the study and were assessed according to the NCI CTCAE Version 5.0 (November 27, 2017).
[0080] result A total of 90 patients were enrolled in this study. Of these, 45 patients were in Arm-I (NRC-2694-A + chemotherapy) and 45 patients were in Arm-II (chemotherapy alone). Of the 45 patients in Arm-I, there were 40 men and 5 women, with a median age of 50 years (range 31-66). Of the 45 patients in Arm-II, there were 41 men and 4 women, with a median age of 51 years (range 30-64). The mean height and weight of the patients in Arm-I at baseline were 164.0 cm (± 7.36) and 51.0 kg (± 9.32), respectively. The mean height and weight of the patients in Arm-II at baseline were 167.0 cm (± 7.69) and 53.2 kg (± 9.7), respectively. Detailed patient demographics are listed in Table 2. Patients with ECOG performance status ≤ 2 and who met the eligibility criteria were enrolled. Of the 90 patients enrolled, 67 patients who completed at least two cycles of chemotherapy or one radiological evaluation were evaluated for response evaluation. Of these 67 patients, 34 patients were in Arm-I and 33 patients were in Arm-II.
[0081] [Table 2]
[0082] Efficacy evaluation Progression-free survival (PFS) We found that the median progression-free survival (PFS) was 4.38 months in patients in Arm-I and 1.38 months in Arm-II (hazard ratio for PFS: 0.436, 95% CI: 0.264-0.722, p<0.0007). Incorporation of NRC-2694-A into a paclitaxel and platinum chemotherapy regimen was associated with a significant prolongation of PFS (Table 3). Kaplan-Meier estimates of progression-free survival by treatment group are shown in Figure 1.
[0083] [Table 3]
[0084] Efficacy assessment: Objective response rate (ORR) The inclusion of NRC-2694-A in the chemotherapy regimen significantly increased the ORR in patients in Arm-I compared with those in Arm-II. Complete responses were observed in five patients in Arm-I compared with two patients in Arm-II. Partial responses were observed in 12 patients in Arm-I compared with five patients in Arm-II. The ORR observed in Arm-1 was 50% compared with 21% in Arm-II, with a p-value of 0.016 (Table 4).
[0085] [Table 4]
[0086] Efficacy evaluation: Patients who transitioned from the chemotherapy alone group to the NRC-2694-A and chemotherapy group The study protocol allowed patients whose disease progressed after two cycles of chemotherapy in Arm-II (chemotherapy alone group) to receive NRC-2694-A in addition to chemotherapy. Seven patients whose disease progressed after two cycles in Arm-II subsequently received NRC-2694-A and chemotherapy. Of these patients, two patients achieved a complete response, the other two had stable disease, and one patient progressed. This indicates that patients whose disease progressed after failure of chemotherapy demonstrated a complete response after incorporation of NRC-2694-A.
[0087] Efficacy evaluation: Patients who continued to Stage-II (monotherapy) In addition, 11 patients who completed stage-I treatment [Arm-I (9 patients), Arm-II (2 patients)] continued to stage-II (monotherapy). Of the 9 patients in Arm-I, 2 had a complete response, 4 had a partial response, 2 had stable disease, and 1 had progressive disease at the start of monotherapy.
[0088] Two patients maintained a complete response during stage II. Of the four patients who had a partial response in stage I, one patient continued to have a partial response, two had stable disease, and one had progressive disease. Two patients with stable disease in stage I continued to have stable disease. However, one patient with progressive disease in stage I continued to have progressive disease.
[0089] Of note, two patients in Arm-II who previously showed partial response and stable disease achieved complete response in Stage-II, indicating that NRC-2694-A has therapeutic benefit not only in combination with chemotherapy but also as monotherapy.
[0090] The outcomes of patients who progressed to stage II are summarized in Figure 2.
[0091] Discussion and conclusion A randomized phase II study of recurrent head and neck squamous cell carcinoma showed that the addition of NRC-2694-A to paclitaxel and cisplatin / carboplatin chemotherapy significantly extended progression-free survival. Cisplatin resistance in cancer treatment is determined by overexpression of the EGFR tyrosine kinase receptor and inhibition of cell death due to increased expression of antiapoptotic proteins in patients with poor prognosis who received neoadjuvant cisplatin treatment. The phenomenon of multidrug resistance (MDR) during chemotherapy is one of the reasons for the limited clinical efficacy of chemotherapeutic agents. Importantly, overexpression of epidermal growth factor receptor (EGFR) or any of its related pathways occurs in more than 90% of head and neck cancers. Increased expression of EGFR protein or amplification of EGFR gene copy number is associated with poor prognosis, radioresistance, local treatment failure and increased rate of distant metastasis. One of the reasons for EGFR overexpression is due to radiation therapy, which is the standard treatment for head and neck cancer, and such overexpression can further lead to disease recurrence.
[0092] The phase III clinical trial of pembrolizumab in R / M HNSCC, KEYNOTE-048, demonstrated an ORR of 36% with pembrolizumab in combination with platinum-based chemotherapy compared with 26% with pembrolizumab alone in the CPS>20 population (Burtness et al, The Lancet, 2019; 394(10212): 1915-1928). Platinum-based chemotherapy alone without targeted therapy demonstrated only a 19.5% response rate. In the same trial, cetuximab demonstrated an ORR of 35.6% when combined with platinum-based chemotherapy (Vermorken et al, New England Journal of Medicine, 2008; 359(11): 1116-27).
[0093] In contrast, NRC-2694-A demonstrated better efficacy in terms of PFS and ORR. The addition of NRC-2694-A to chemotherapy was associated with a statistically significant increase in median progression-free survival by 3 months. The study demonstrated a statistically significant improvement in PFS. NRC-2694-A, in combination with platinum-based chemotherapy, also significantly extended ORR compared with chemotherapy alone, with a favorable safety profile. Patients who received NRC-2694-A as monotherapy after completion of chemotherapy also demonstrated objective responses. This finding is important, as these patients would have disease progression if not treated. Thus, continuation of NRC-2694-A after chemotherapy will continue to control disease in patients with no other treatment options.
[0094] The response rate observed with NRC-2694-A is observed to be better than that of approved monoclonal antibodies, namely cetuximab and pembrolizumab. Importantly, all currently approved treatment options for R / M HNSCC are injectable and require supervised administration in a hospital setting. Furthermore, to date, there are no orally active treatment options approved for R / M HNSCC. NRC-2694-A is an orally active tyrosine kinase inhibitor for the treatment of R / M HNSCC.
[0095] In conclusion, NRC-2694-A not only improved progression-free survival and objective responses in combination with platinum-based chemotherapy, but also benefited patients with recurrent head and neck squamous cell carcinoma when administered as monotherapy. It is clear that NRC-2694-A could be an important treatment option in recurrent and / or metastatic head and neck cancer.
Claims
1. A therapeutic agent for treating recurrent and / or metastatic head and neck squamous cell carcinoma in a patient, comprising a compound as an active ingredient, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutical acceptable salt thereof.
2. The method according to claim 1, wherein the recurrent and / or metastatic head and neck squamous cell carcinoma is recurrent head and neck squamous cell carcinoma.
3. The method according to claim 2, wherein the recurrent head and neck squamous cell carcinoma is metastatic recurrent head and neck squamous cell carcinoma.
4. The method of claim 1, wherein the treatment of recurrent and / or metastatic head and neck squamous cell carcinoma comprises reducing the size of tumors associated with recurrent and / or metastatic head and neck squamous cell carcinoma.
5. A reduction in tumor size of at least 10% from baseline; Optionally, the size of the tumor is measured according to RECIST criteria version 1.1; The therapeutic agent according to claim 4.
6. The method of claim 1, wherein the recurrent and / or metastatic head and neck squamous cell carcinoma is resistant to radiation therapy and / or chemotherapy.
7. 1. A method for treating recurrent and / or metastatic head and neck cancer in a patient, comprising: comprising a compound as an active ingredient, the compound being (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutically acceptable salt thereof; and A therapeutic agent, wherein treating head and neck cancer includes reducing the size of one or more tumors associated with head and neck cancer.
8. The method according to claim 7, wherein the head and neck cancer is recurrent head and neck cancer.
9. The method of claim 7, wherein the head and neck cancer is metastatic.
10. The method according to claim 7, wherein the head and neck cancer is head and neck squamous cell carcinoma.
11. A reduction in tumor size of at least 10% from baseline; Optionally, the size of the tumor is measured according to RECIST criteria version 1.1; The therapeutic agent according to claim 7.
12. The method of claim 7, wherein the head and neck cancer is resistant to radiation therapy and / or chemotherapy.
13. The method of claim 1 or 7, wherein the patient has undergone at least one line of cancer therapy prior to treatment with the compound.
14. The method of claim 1 or 7, wherein the patient has undergone at least two lines of cancer therapy prior to treatment with the compound.
15. The method of claim 1 or 7, wherein the patient is a human patient.
16. 10. A compound for therapeutic use according to claim 1 or 7, wherein the patient is male or female.
17. The method of claim 1 or 7, wherein the patient is male.
18. The method of claim 1 or 7, wherein the patient is between 18 and 90 years old.
19. The method of claim 1 or 7, wherein the patient is between 30 and 70 years old.
20. The method of claim 1 or 7, wherein the compound is NRC-2694 dihydrochloride (NRC-2694-A) or NRC-2694 monohydrochloride (NRC-2694-B).
21. The method of claim 1 or 7, wherein the compound is NRC-2694 dihydrochloride (NRC-2694-A).
22. The method of claim 1 or 7, wherein the compound is administered orally to the patient.
23. The method of claim 1 or 7, wherein the compound is administered to the patient in the form of a tablet or capsule.
24. 10. The method of claim 1 or 7, wherein the compound is administered to the patient once or twice daily.
25. The method of claim 1 or 7, wherein the compound is administered to the patient once daily.
26. 10. The compound for use according to claim 1 or 7, wherein the compound is administered to the patient at a dose of from 50 mg / day to 500 mg / day.
27. 10. The method of claim 1 or 7, wherein the compound is administered to the patient at a dose of from 100 mg / day to 400 mg / day.
28. 10. The therapeutic agent of claim 1 or 7, wherein the compound is for use in combination with: (a) cisplatin and paclitaxel or (b) carboplatin and paclitaxel.
29. 1. Use of a compound in the manufacture of a medicament for the treatment of a patient with recurrent and / or metastatic head and neck squamous cell carcinoma, wherein the compound is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutical acceptable salt thereof.
30. Use of a compound in the manufacture of a therapeutic agent for a patient with recurrent and / or metastatic head and neck cancer, wherein the compound is (3-ethynyl-phenyl)-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yl]-amine (NRC-2694) or a pharma- ceutically acceptable salt thereof; The use, wherein treating head and neck cancer comprises reducing the size of one or more tumors associated with the head and neck cancer.
Citation Information
Patent Citations
6,7-dialkoxyquinazoline derivatives useful in the treatment of cancer-related diseases
JP2011509995A
Cited By
EGFR inhibitor for the treatment of head and neck cancer
US12773410B2
